A detailed history of Ameritas Investment Partners, Inc. transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, Ameritas Investment Partners, Inc. holds 3,832 shares of URGN stock, worth $44,259. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,832
Previous 2,816 36.08%
Holding current value
$44,259
Previous $47,000 2.13%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$12.7 - $17.92 $12,903 - $18,206
1,016 Added 36.08%
3,832 $48,000
Q4 2023

Feb 14, 2024

BUY
$10.87 - $15.93 $13,043 - $19,116
1,200 Added 74.26%
2,816 $42,000
Q2 2023

Aug 11, 2023

BUY
$8.75 - $14.29 $14,140 - $23,092
1,616 New
1,616 $16,000
Q2 2022

Aug 12, 2022

SELL
$5.12 - $8.74 $8,463 - $14,447
-1,653 Closed
0 $0
Q2 2019

Aug 14, 2019

BUY
$32.75 - $40.35 $54,135 - $66,698
1,653 New
1,653 $59,000

Others Institutions Holding URGN

About UroGen Pharma Ltd.


  • Ticker URGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 22,740,500
  • Market Cap $263M
  • Description
  • UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...
More about URGN
Track This Portfolio

Track Ameritas Investment Partners, Inc. Portfolio

Follow Ameritas Investment Partners, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ameritas Investment Partners, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Ameritas Investment Partners, Inc. with notifications on news.